Skip to main content
Subscribe
Sign in
Menu
Membership
Events
Knowledge Center
About
Register
Search
Sign In
Sign In
Register
Subscribe
Pfizer
Latest Articles
Alan Schwartz Makes Guggenheim Partners an M&A Player
David Rothnie
October 7, 2016
Daily Agenda: Oil Prices Fall on Robust Supply
Andrew Barber
August 24, 2016
Daily Agenda: Mixed Signals Complicate Fed Prediction
Andrew Barber
August 22, 2016
U.S. M&A Could Rebound as Companies See Few Other Growth Options
Dan Weil
·
July 6, 2016
Investing in a Cure for Cancer
Kaitlin Ugolik
June 7, 2016
Perella Weinberg’s Andrew Bednar Drives Stock Exchange Megadeals
David Rothnie
·
April 19, 2016
Takeover Veteran Paul Taubman Aims High with PJT Partners
David Rothnie
January 19, 2016
Investing in the Health Care Revolution
Kaitlin Ugolik
January 4, 2016
Allergan-Pfizer Merger Gives Pharma a Growth Injection
Anne Szustek
December 16, 2015
Daily Agenda: Commodity Rout Continues
Andrew Barber
November 23, 2015
Daily Agenda: Liquidity Fuels Continuing M&A Boom
Andrew Barber
October 30, 2015
Ben Thorpe Helps Keep Goldman’s Health M&A Franchise in Top Shape
David Rothnie
June 22, 2015
The 2015 Hedge Fund Rising Stars: Monica Lai
Tyler Davies
June 15, 2015
Daily Agenda: Can U.S. Strength Kick-start Global Growth?
Andrew Barber
January 27, 2015
In Event-Driven Strategy Hedge Funds, M&A is the Headliner
David Turner
May 13, 2014
The New Logic of M&A
Joseph G Paul
May 8, 2014
Spurt of Initial Public Offerings Fails to Lift VC-Backed Companies
Udayan Gupta
April 24, 2013
How to Profit from Faster FDA and Better Science
Fran Hawthorne
August 1, 2012
More Articles